Results 21 to 30 of about 2,631,955 (205)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma [PDF]

Frontiers in Oncology, 2021
BackgroundOsteosarcoma (OTS) is aggressive bone malignancy without well-recognized prognosis biomarker. Tumor mutational burden (TMB) has been proved as effective biomarker in predicting clinical outcomes in several cancer types. However, its prognostic value in OTS remains unknown.
Lu Xie, Yufei Yang, Wei Guo, Dongxue Che, Jie Xu, Xin Sun, Kuisheng Liu, Tingting Ren, Xingyu Liu, Yi Yang, Tao Ji, Xiaodong Tang   +11 more
openaire   +3 more sources

Tumor mutation burden and tumor content of exome-sequenced samples.

, 2022
Tumor mutation burden and tumor content of exome-sequenced samples.
Victoria Zismann (5724659), Rebecca Halperin (4526026), Natalia Briones (13141723), Samuel Stewart (6206336), Jacob Cawley (13141720), Nieves Perdigones (5724668), Salvatore Facista (13141729), Keith Richter (13141726), Shukmei Wong (339845), Jeffrey M. Trent (9110592), William P. D. Hendricks (5495867), Karthigayini Sivaprakasam (5724662), Tania Contente-Cuomo (485065), Chand Khanna (219274), Muhammed Murtaza (372357), E. J. Ehrhart (9388761)   +15 more
core   +1 more source

Tumor gene mutation burden of squamous cell carcinomas.

, 2023
Tumor gene mutation burden of squamous cell carcinomas.
Tsutomu Daa (13920784), Yuzo Oyama (12528764), Yoshihiko Kondo (536169), Haruto Nishida (13920772), Kazuhiro Kawamura (120345), Takahiro Kusaba (14609095)   +5 more
core   +1 more source

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds [PDF]

Nature Communications, 2021
Abstract Spontaneous canine cancers are valuable but relatively understudied and underutilized models. To enhance their usage, we reanalyze whole exome and genome sequencing data published for 684 cases of >7 common tumor types and >35 breeds, with rigorous quality control and breed validation.
Burair A. Alsaihati, Kun-Lin Ho, Joshua Watson, Yuan Feng, Tianfang Wang, Kevin K. Dobbin, Shaying Zhao   +6 more
openaire   +3 more sources

Evaluation of correlation between histopathologic and bioinformatic assessment of tumor content and tumor mutation burden.

, 2022
For each of the cases with three independently sequenced tumor sections, the Pearson correlation coefficient was calculated for: A) Median variant allele fraction (AF) versus histologically and bioinformatically determined tumor content estimates; and B)
Victoria Zismann (5724659), Rebecca Halperin (4526026), Natalia Briones (13141723), Samuel Stewart (6206336), Jacob Cawley (13141720), Nieves Perdigones (5724668), Salvatore Facista (13141729), Keith Richter (13141726), Shukmei Wong (339845), Jeffrey M. Trent (9110592), William P. D. Hendricks (5495867), Karthigayini Sivaprakasam (5724662), Tania Contente-Cuomo (485065), Chand Khanna (219274), Muhammed Murtaza (372357), E. J. Ehrhart (9388761)   +15 more
core   +1 more source

Supplementary Data from Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer

, 2022
Supplementary Data from Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck ...
Ilya G. Serebriiskii (15044919), Emmanuelle Nicolas (15044922), Yasmine Baca (15044916), Joanne Xiu (5024744), Erica A. Golemis (14949004), W. Michael Korn (15021032), Barbara Burtness (550227), Trisha Wise-Draper (15044928), Alexander Y. Deneka (15044913), Michael J. Demeure (15044925), Ammar Sukari (824369), Theodore T. Nguyen (8561148), Mitchell I. Parker (14956779)   +12 more
core   +1 more source

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer [PDF]

, 2023
SYNE1, a nuclear envelope protein critical for cellular structure and signaling, is downregulated in numerous malignancies. SYNE1 alterations are found in 10% of gynecologic malignancies and 5% of epithelial ovarian cancers. Previous studies demonstrated
Laura M. Harbin, Harbin, Laura M., Jill M. Kolesar, Nan Lin, Frederick R. Ueland, Kolesar, Jill M., Lin, Nan, Ueland, Frederick R.   +7 more
core   +1 more source

High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival

Cancer Medicine, 2020
Background High tumor mutation burden is shown to be associated with a poor clinical outcome. As the tumor‐derived fraction of circulating cell‐free DNA (cfDNA) is shown to reflect the genetic spectrum of the tumor, we examined whether the mutation ...
Jouni Kujala, Jaana M. Hartikainen, Maria Tengström, Reijo Sironen, Veli‐Matti Kosma, Arto Mannermaa   +5 more
doaj   +1 more source

Clinical Impact of Tumor Mutational Burden in Neuroblastoma [PDF]

JNCI: Journal of the National Cancer Institute, 2018
Abstract Background Neuroblastoma is the most common pediatric extracranial solid tumor. Within conventional risk groups, there is considerable heterogeneity in outcomes, indicating the need for improved risk stratification.
William L, Hwang, Rachel L, Wolfson, Andrzej, Niemierko, Karen J, Marcus, Steven G, DuBois, Daphne, Haas-Kogan   +5 more
openaire   +2 more sources

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing

BMC Cancer, 2021
Background Tumor mutation burden is an emerging biomarker for immunotherapy. Although several clinical trials for immunotherapy in lymphoma have been carried out, the mutation burden of various lymphomas is not well known yet. Thus, the objective of this
Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim   +4 more
doaj   +1 more source